Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system

W. Stöhr; T. Langer; A. Kremers; S. Bielack; A. Lamprecht-Dinnesen; E. Frey; J. D. Beck

doi:10.1081/CNV-200055951

Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system

W. Stöhr, T. Langer, A. Kremers, S. Bielack, A. Lamprecht-Dinnesen, E. Frey, J. D. Beck^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Kinder- und Jugendmedizin

63 Zitate (Scopus)

Abstract

The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m²) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m², almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.

Originalsprache	Englisch
Zeitschrift	Cancer Investigation
Jahrgang	23
Ausgabenummer	3
Seiten (von - bis)	201-207
Seitenumfang	7
ISSN	0735-7907
DOIs	https://doi.org/10.1081/CNV-200055951
Publikationsstatus	Veröffentlicht - 2005

Fördermittel

This study was supported by ‘‘Deutsche Krebshilfe.’’ Below is a list of participating centers (and the number of study patients). Supporters include both children’s hospitals and medical/orthopedic hospitals: Prof. Dr. R. Mertens, Children’s Hospital, TH Aachen (4) Dr. A. Gnekow, University Hospital for Children, Augsburg (3) Prof. Dr. P. Imbach, Universitiy Hospital for Children, Basel (3) Prof. Dr. G. Henze, University Hospital for Children, Berlin (15) Prof. Dr. U. Bode, University Hospital for Children, Bonn (6) Dr. W. Eberl, Children’s Hospital, Braunschweig (1) PD Dr. V. Gerein, Children’s Hospital, Gummersbach (2) Prof. Dr. F. M. Fink, University Hospital for Children, Innsbruck (4) Dr. A. Leipold, Children’s Hospital, Karlsruhe (1) Prof. Dr. D. Körholz, University Hospital for Children, Leipzig (4) Prof. Dr. D. Reinhardt, University Hospital for Children, Munich (2) Prof. Dr. H. Jürgens, University Hospital for Children, Münster (23) Prof. Dr. J. Treuner, University Hospital for Children, Stuttgart (7) Prof. Dr. D. Niethammer, University Hospital for Children, Tübingen (2) Prof. Dr. H. Gadner, University Hospital for Children, Wien (16) Prof. Dr. M. Fey, Medical Hospital, Bern (3) Prof. Dr. H. Rasche, Medical Hospital, Bremen (1) Prof. Dr. G. Dölken, Medical Hospital of the University, Greifswald (1) Prof. Dr. G. von Salis-Soglio, Medical Hospital, Orthopedic section, Leipzig (1) Dr. C. Kerber, Medical Hospital, Schwerin (1) General practitioners (1)

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Dokumente

10.1081/CNV-200055951

Weitere Links

Link to publication in Scopus

Zitieren

@article{e557500a5df44bbf9c2425a8991636fc,

title = "Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system",

abstract = "The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m2) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51\% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m2, almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.",

author = "W. St{\"o}hr and T. Langer and A. Kremers and S. Bielack and A. Lamprecht-Dinnesen and E. Frey and Beck, \{J. D.\}",

note = "Funding Information: This study was supported by {\textquoteleft}{\textquoteleft}Deutsche Krebshilfe.{\textquoteright}{\textquoteright} Below is a list of participating centers (and the number of study patients). Supporters include both children{\textquoteright}s hospitals and medical/orthopedic hospitals: Prof. Dr. R. Mertens, Children{\textquoteright}s Hospital, TH Aachen (4) Dr. A. Gnekow, University Hospital for Children, Augsburg (3) Prof. Dr. P. Imbach, Universitiy Hospital for Children, Basel (3) Prof. Dr. G. Henze, University Hospital for Children, Berlin (15) Prof. Dr. U. Bode, University Hospital for Children, Bonn (6) Dr. W. Eberl, Children{\textquoteright}s Hospital, Braunschweig (1) PD Dr. V. Gerein, Children{\textquoteright}s Hospital, Gummersbach (2) Prof. Dr. F. M. Fink, University Hospital for Children, Innsbruck (4) Dr. A. Leipold, Children{\textquoteright}s Hospital, Karlsruhe (1) Prof. Dr. D. K{\"o}rholz, University Hospital for Children, Leipzig (4) Prof. Dr. D. Reinhardt, University Hospital for Children, Munich (2) Prof. Dr. H. J{\"u}rgens, University Hospital for Children, M{\"u}nster (23) Prof. Dr. J. Treuner, University Hospital for Children, Stuttgart (7) Prof. Dr. D. Niethammer, University Hospital for Children, T{\"u}bingen (2) Prof. Dr. H. Gadner, University Hospital for Children, Wien (16) Prof. Dr. M. Fey, Medical Hospital, Bern (3) Prof. Dr. H. Rasche, Medical Hospital, Bremen (1) Prof. Dr. G. D{\"o}lken, Medical Hospital of the University, Greifswald (1) Prof. Dr. G. von Salis-Soglio, Medical Hospital, Orthopedic section, Leipzig (1) Dr. C. Kerber, Medical Hospital, Schwerin (1) General practitioners (1) Copyright: Copyright 2008 Elsevier B.V., All rights reserved.",

year = "2005",

doi = "10.1081/CNV-200055951",

language = "English",

volume = "23",

pages = "201--207",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor \& Francis Group LLC Philadelphia",

number = "3",

}

TY - JOUR

T1 - Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system

AU - Stöhr, W.

AU - Langer, T.

AU - Kremers, A.

AU - Bielack, S.

AU - Lamprecht-Dinnesen, A.

AU - Frey, E.

AU - Beck, J. D.

N1 - Funding Information: This study was supported by ‘‘Deutsche Krebshilfe.’’ Below is a list of participating centers (and the number of study patients). Supporters include both children’s hospitals and medical/orthopedic hospitals: Prof. Dr. R. Mertens, Children’s Hospital, TH Aachen (4) Dr. A. Gnekow, University Hospital for Children, Augsburg (3) Prof. Dr. P. Imbach, Universitiy Hospital for Children, Basel (3) Prof. Dr. G. Henze, University Hospital for Children, Berlin (15) Prof. Dr. U. Bode, University Hospital for Children, Bonn (6) Dr. W. Eberl, Children’s Hospital, Braunschweig (1) PD Dr. V. Gerein, Children’s Hospital, Gummersbach (2) Prof. Dr. F. M. Fink, University Hospital for Children, Innsbruck (4) Dr. A. Leipold, Children’s Hospital, Karlsruhe (1) Prof. Dr. D. Körholz, University Hospital for Children, Leipzig (4) Prof. Dr. D. Reinhardt, University Hospital for Children, Munich (2) Prof. Dr. H. Jürgens, University Hospital for Children, Münster (23) Prof. Dr. J. Treuner, University Hospital for Children, Stuttgart (7) Prof. Dr. D. Niethammer, University Hospital for Children, Tübingen (2) Prof. Dr. H. Gadner, University Hospital for Children, Wien (16) Prof. Dr. M. Fey, Medical Hospital, Bern (3) Prof. Dr. H. Rasche, Medical Hospital, Bremen (1) Prof. Dr. G. Dölken, Medical Hospital of the University, Greifswald (1) Prof. Dr. G. von Salis-Soglio, Medical Hospital, Orthopedic section, Leipzig (1) Dr. C. Kerber, Medical Hospital, Schwerin (1) General practitioners (1) Copyright: Copyright 2008 Elsevier B.V., All rights reserved.

PY - 2005

Y1 - 2005

N2 - The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m2) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m2, almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.

AB - The aim of this study was to analyze cisplatin-induced ototoxicity in a recent study trial. Seventy-four patients who had received cisplatin for the treatment of osteosarcoma (median cumulative dose: 360 mg/m2) were investigated prospectively for ototoxicity in a multicenter trial. Hearing function was tested by audiometry. We evaluated the incidence and dependencies of hearing loss. After cessation of therapy, 51% of the patients showed a hearing loss of > 20 dB in the frequency range of 4-8 kHz. Only in one patient a hearing loss was found at 2 kHz, and in none at 1 kHz. At a cumulative cisplatin dose of ≤ 240 mg/m2, almost no ototoxicity was found. Incidence and magnitude of hearing loss increased significantly with a higher cumulative dose. Furthermore, hearing thresholds were significantly poorer in children < 12 years. A further follow-up investigation showed only a marginal change in hearing function. We conclude that ototoxicity is moderate in our group of patients and probably irreversible.

UR - https://www.scopus.com/pages/publications/18944370353

U2 - 10.1081/CNV-200055951

DO - 10.1081/CNV-200055951

M3 - Journal articles

C2 - 15945505

AN - SCOPUS:18944370353

SN - 0735-7907

VL - 23

SP - 201

EP - 207

JO - Cancer Investigation

JF - Cancer Investigation

IS - 3

ER -

Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system

Abstract

Fördermittel

UN SDGs

Strategische Forschungsbereiche und Zentren

Dokumente

Weitere Links

Fingerprint

Zitieren